Oak vs. Found: Two Structured Programs, One Verdict

If you want more than just a prescription — if you want a provider who checks in on your progress, adjusts your treatment, and offers clinical guidance alongside medication — your realistic options narrow quickly. Oak and Found are two of the few GLP-1 telehealth platforms that build structured programs around the prescription rather than treating medication delivery as the entire product.

Both are semaglutide-focused. Both include clinical monitoring. Both target patients who want support, not just a vial in the mail. But they differ on format, pricing, and what "structured support" actually looks like in practice.

Side by Side

What "Structured Program" Actually Means

Oak's model: coaching-inclusive

Oak positions itself as a comprehensive weight management program, not just a medication delivery service. Their model includes regular coaching check-ins, clinical monitoring, and a more thorough intake process (their questionnaire takes about 12 minutes — longer than the industry average). The program is designed to address behavior, nutrition, and activity alongside medication.

Oak's pricing isn't published on a simple landing page — they use a structured program model where cost depends on the program you enroll in. Their GLP-1 landing page focuses on injectable semaglutide; oral drops are listed as "coming soon." Prescriber review takes up to 24 hours, and pharmacy fulfillment runs 2–4 days, putting total intake at 4–6 days.

The trade-off: Oak is slower and less price-transparent than Found. If you want to know exactly what you'll pay before signing up, Oak's model requires more engagement with their intake flow before you see numbers.

Found's model: clinical monitoring + oral format

Found offers structured clinical monitoring within a more transparent pricing framework. Their semaglutide dissolvable tablets cost $189 per 4-week cycle — a clear, published rate. A $100-off promo on the first order brings month one to approximately $89. Provider check-ins are included in the program, and Found's team monitors your progress and adjusts treatment as needed.

Found's key differentiator from Oak is format: dissolvable semaglutide tablets rather than injectables. For patients who want clinical structure but prefer not to self-inject, Found is one of very few options that combine a structured program with an oral delivery format. Their intake is also faster — same-day prescriber review and 2–3 day pharmacy fulfillment, totaling 3–4 days.

The trade-off: Found's program is clinical monitoring, not coaching in the way Oak defines it. If you want behavioral coaching, nutrition planning, and activity guidance built into your program, Oak's model is more comprehensive. If you want medication monitoring with provider check-ins and a simpler experience, Found delivers that efficiently.

The Format Question: Injectable vs. Oral

This may be the biggest deciding factor. Oak is injectable-only right now. Found offers dissolvable tablets. If you have a strong preference for one format over the other, your decision is essentially made.

Injectable semaglutide has the longest clinical track record and the most data behind it. Dissolvable tablets are a newer compounded format with less long-term data but meaningful convenience advantages: no needles, no refrigeration, no injection-site reactions. Both formats deliver semaglutide; the difference is in delivery, not the molecule itself.

For a broader look at oral GLP-1 options across the market, see our oral format comparison.

Who Neither Is For

Both Oak and Found are semaglutide-only platforms. If you want tirzepatide, neither provider offers it. For tirzepatide access, see our tirzepatide access comparison.

If you don't want a structured program — you just want medication delivered without coaching calls or scheduled check-ins — providers like GobyMeds ($99/month, no subscription) or Wellorithm ($147/month oral tablets) deliver medication with minimal overhead. Our intake speed ranking covers the fastest options.

Methodology

Program features and pricing verified against provider websites and intake flows as of September 2026. Intake timing based on our most recent walkthroughs. Clinical model descriptions reflect what each provider's patient-facing materials describe; we have not independently audited the quality or frequency of clinical interactions. See our full methodology.